608

DRUG3 trials

Sponsors

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Conditions

Axial SpondyloarthritisAxial Spondyloarthritis, Non-RadiographicModerate to Severe Plaque Psoriasis

Phase 1

Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Moderate to Severe Plaque Psoriasis

Start: 2019-11-25End: 2020-10-31Target: 62Updated: 2020-04-29

Phase 2

A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

RecruitingNCT06222671

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Axial Spondyloarthritis

Start: 2024-03-22End: 2025-11-30Target: 180Updated: 2025-03-11

Phase 3

A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

Not yet recruitingNCT07349329

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Axial Spondyloarthritis, Non-Radiographic

Start: 2026-03-09End: 2029-02-21Target: 380Updated: 2026-01-16